Conference Call and Webcast to Follow
GERMANTOWN, Md., Feb. 29 /PRNewswire-FirstCall/ -- MiddleBrook Pharmaceuticals, Inc. (Nasdaq: MBRK), a pharmaceutical company focused on developing and commercializing novel anti-infective products, today announced it will release results for the quarter and fiscal year ended December 31, 2007, on Tuesday, March 4, 2008, before the market opens. A full text copy of the release will be disseminated at that time.
Edward M. Rudnic, Ph.D., president and chief executive officer, will
host a conference call to discuss the results and other corporate
developments at 10:30 AM ET on Tuesday, March 4, 2008. Also participating
on the call will be Robert C. Low, vice president, finance and CFO. To
participate in the conference call, dial the appropriate number below
shortly before the 10:30 AM start time and ask for the MiddleBrook
Pharmaceuticals conference call hosted by Dr. Rudnic.
The teleconference dial-in numbers are as follows:
Domestic callers 1-800-813-8504
International callers 1-706-643-7752
The conference call will be broadcast simultaneously and archived on the Company's web site, http://www.middlebrookpharma.com. Investors should go to the web site at least 15 minutes early to register, download, and install any necessary audio software.
A replay of the call will be available on Tuesday, March 4, 2008, beginning at 12:30 PM ET and will be accessible until Tuesday, March 11, 2008, at 5:00 PM ET. The replay call-in number is 1-800-642-1687 for domestic callers and 1-706-645-9291 for international callers. The access number is 37507035.
ABOUT MIDDLEBROOK PHARMACEUTICALS:
MiddleBrook Pharmaceuticals, Inc. (Nasdaq: MBRK) is a pharmaceutical company focused on the development and commercialization of anti-infective drug products that fulfill substantial unmet medical needs in the treatment of infectious disease. The Company is developing anti-infective drugs based on its novel biological finding that bacteria exposed to antibiotics in front-loaded staccato bursts, or "pulses," are killed more efficiently and effectively than those under standard treatment regimens. Based on this finding, MiddleBrook has developed a proprietary, once-a-day pulsatile delivery technology called PULSYS(R). The Company currently markets the Keflex(R) brand of cephalexin and has received regulatory approval for MOXATAG(TM) -- the first and only once-daily amoxicillin product approved for marketing in the U.S. For more on MiddleBrook, please visit http://www.middlebrookpharma.com.
|SOURCE MiddleBrook Pharmaceuticals, Inc.|
Copyright©2008 PR Newswire.
All rights reserved